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Coronary heart disease incidence and
mortality, and all-cause mortality among
diabetic and non-diabetic people according
to their smoking behavior in Finland
Noël C. Barengo1*, Yvonne Teuschl2, Vladislav Moltchanov3, Tiina Laatikainen3,4,5, Pekka Jousilahti4
and Jaakko Tuomilehto2,3,6,7

Abstract
Background: As type 2 diabetes (T2D) patients have a high risk for coronary heart disease (CHD) and all-cause
mortality and smoking is a major single risk factor for total and CHD mortality, it is important to understand the
impact of smoking to the outcome events in comparison to people without T2D. Studies of excess risk of CHD
incidence and mortality, and all-cause mortality in T2D patients related to smoking are controversial. We aimed to
assess the risk of CHD incidence and mortality, and all-cause mortality in a large Finnish population cohort
consisting of people with and without T2Daccording to smoking status.
Methods: Prospective follow-up of 28 712 men and 30 700 women aged 25–64 years living in eastern and southwestern Finland. The data on mortality were obtained from the nationwide death register using the unique
national personal identification number. Follow-up information regarding CHD was based on the Finnish Hospital
Discharge Register for non-fatal outcomes. The Cox proportional hazards models were used to estimate the
association between diabetes and smoking subgroups and the risk for total and CHD mortality.
Results: T2D patients who were smoking had higher all-cause mortality in both men (HR 3.76; 95% CI 2.95-4.78) and
women (HR 4.51; 95% CI 2.91-7.00) than non-smoking diabetic men (HR 2.03; 95% CI 1.51-2.74) and women (HR 2.11;
95% CI 1.71-2.59). The CHD mortality risk for smoking men with T2D was higher (HR 6.15; 95% CI 4.22-8.96) than in
non-smoking diabetic men (HR 2.62; 95% CI 1.60-4.29). Similar results were found in women revealing corresponding
HR for CHD mortality of 6.92 (95% CI 2.79-17.19) for smoking, T2D women and 4.06 (95% CI 2.83-5.82) for non-smoking
T2D women, respectively. Even though the risk of CHD incidence in T2D patients who had stopped smoking was
statistically significantly higher than in their non-smoking non-diabetic counterparts, their CHD incidence was lower
than in smoking T2D patients (HR in men 3.00; HR in women 2.80).
Conclusion: It is important to address tobacco consumption in T2D patients, especially during primary health care
contacts in order to reduce their high risk of CHD and all-cause mortality.
Keywords: Smoking, Diabetes mellitus, Mortality, Coronary heart disease
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Background
Type 2 diabetes (T2D) is one of the fastest growing public
health problems in both developed and developing countries imposing a high financial burden on health care
costs. The IDF has estimated that the numbers of adults
with diabetes is expected to rise from 415 million in 2015
to 642 million by 2040 [1]. Most people with diabetes will
sooner or later develop cardiovascular diseases (CVD) [2].
People with T2D have a higher risk of CVD and all-cause
mortality than the rest of the population and once developing CVD their prognosis are poorer [3, 4]. Premature
mortality caused by diabetes results in an estimated 12–14
years of life lost [5].
Studies of excess risk of coronary heart disease (CHD)
and all-cause mortality in T2D patients related to smoking are controversial. This is surprising as smoking is
one of the classical risk factors for CVD besides hypertension, hyperlipidaemia and diabetes, and contributes
substantially to the global burden of disease [6, 7]. While
some studies observed an additive increased risk of
CHD and all-cause mortality [8–12], others did not find
that smoking amplifies the risk of CHD or total mortality rates among T2D patients [13–17]. It has been argued that these conflicts may be attributed to low power
or inadequate adjustment for confounders [18].
As T2D patients have shown to have a high risk for
CHD and all-cause mortality and smoking is a major
single risk factor for total and CHD mortality, it is important to understand the impact of smoking to these
outcome events in people with T2D in comparison with
people without T2D.
The aim of this study was to assess the risks of CHD
and all-cause mortality in a large Finnish population cohort consisting of people with and without diabetes according to smoking status.

Methods
Study population

Five independent cross-sectional surveys were carried
out at five-year intervals within the framework of the
FINMONICA/FINRISK studies [19] between 1982 and
2002. An independent random sample was drawn from
the national population register for each survey. The
samples were stratified by sex and 10-year age categories according to the WHO MONICA protocol so that
at least 250 people of each sex and 10-year age group
were chosen [20]. The study participants included in
the five surveys were 25 to 64 years of age, and the
1997 and 2002 surveys also included subjects aged 65
to 74 years. The participation rate varied in the survey
cohorts between 63% and 83% in men and between
72% and 88% in women. The final sample comprised 28
712 men and 30 700 women.
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Baseline data collection

A self-administered questionnaire was mailed to the participants in advance. The questionnaire included questions on health behavior, such as smoking habits, and
physical activity, education and medical history. Smoking
habits were classified to three categories: never smokers,
ex-smokers (those, who had smoked regularly but had
stopped smoking at least six month before the survey)
and current smokers.
The participants reported their occupational and leisure time physical activity. These were merged and
regrouped into three categories (low, moderate and
high) of total physical activity as described in previous
publications [21, 22]. Education level, measured as the
total number of school years, was divided into birth
cohort-specific tertiles.
At the study site, specially trained nurses measured
height, weight, and blood pressure (BP) using a standardized protocol [20]. Height and weight were measured
without shoes and with light clothing. BP was measured
twice from the right arm of the participant in sitting
position after at least 5 min rest. A standard mercury
sphygmomanometer was used. Starting from 1982, BP
was measured twice and the mean of these two BP measurements was used in the analyses.
Serum total cholesterol was determined by using an
enzymatic method (CHOD-PAP, Boehringer Mannheim,
Mannheim, Germany). All samples were analyzed in the
biochemical laboratory of the National Public Health
Institute (nowadays National Institute for Health and
Welfare), which is an accredited laboratory.
Participants who reported having diabetes on the questionnaire, or who had had a hospital discharge diagnosis
of diabetes or the approval for free-of-charge medication
for diabetes before the baseline survey were classified as
having diabetes. Data on diabetes medication were ascertained from the national Social Insurance Institution’s
register on special reimbursement for anti-diabetic drugs
from 1964. Anti-diabetic drugs prescribed by a physician
are reimbursed by social insurance in Finland and are subject to approval of a physician of the Institution who reviews each case history.

CHD incidence and mortality

The original survey data were complemented by linkage
to the nationwide death register of Statistics Finland according the unique national personal identification number that every Finnish resident has. These records covered
the period from January 1970 to December 2008. The
Eighth, Ninth and Tenth Revisions of the International
Classification of Diseases (ICD) were used for coding the
causes of death. The end point of the follow-up was the
date of death.
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Follow-up information regarding CHD was based on
the Finnish Hospital Discharge Register for non-fatal
outcomes. The ICD codes used for CHD incidence and
mortality were as follows: non-fatal myocardial infarction 410–411 (ICD9) and I21–I22 (ICD10) and fatal
cases of CHD 410–414 (ICD9) and I20–I25 (ICD10).
The end points during follow-up was incident CHD, defined as either the first non-fatal CHD or CHD death.
The calendar period of follow up was truncated by the
same date, 31/12/2008, as death information.

for age, study region, study year, education, systolic
blood pressure (SBP), cholesterol level, physical activity,
alcohol consumption and body mass index (BMI) (B).
The data of all six surveys were pooled together as no
first level interaction were found between diabetes/
smoking groups and these variables regarding CHD,
stroke or total mortality, respectively incidence. The proportional hazards assumption in the Cox model was
tested based on the Schoenfeld Residuals. Estimated hazard ratios (HR) and their 95% confidence intervals (CI)
are presented.

Statistical analysis

Statistical analyses were performed using SAS 9.2. The
Cox proportional hazards models were used to estimate
the association between diabetes and smoking subgroups
and the risk for total and CHD mortality. Analyses were
adjusted first for age, study area and study year (A) then

Results
The baseline characteristics of the study participants are
presented in Table 1 according to sex and smoking status. Among men with T2D 32% were current and 37%
ex-smokers. The corresponding prevalence of smoking

Table 1 Baseline characteristics of the study population according to diabetes and smoking status
No diabetes

Diabetes

Non-smokers

Ex-smokersa

Smokersb

Non-smokers

Ex-smokers

Smokers

Men (n)

9539

7063

11054

323

392

341

Age (years)

43.2 (11.9)c

48.5 (11.7)

42.6 (11.1)

54.1 (11.5)

56.9 (9.1)

51.0 (10.4)

Education (%)
Low

28

29

37

31

31

33

Moderate

33

37

35

31

35

34

39

34

28

38

34

33

Body mass index (kg/m2)

High

26.1 (3.5)

27.3 (3.7)

25.8 (3.7)

28.5 (4.4)

29.3 (4.0)

27.8 (4.9)

Systolic blood pressure (mmHg)

140 (18)

144 (20)

142 (19)

148 (24)

148 (21)

146 (21)

Serum cholesterol (mmol/l)

5.8 (1.2)

6.1 (1.2)

6.2 (1.31)

5.7 (1.2)

5.9 (1.3)

6.1 (1.4)

8

10

13

16

21

24

Total physical activity (%)
Low
Moderate

83

84

82

81

77

75

High

9

6

5

3

2

1

Women (n)

21463

2980

5101

878

125

153

Age (years)

45.7 (11.6)

42.5 (11.6)

40.4 (10.8)

54.0 (11.1)

51.2 (11.9)

46.7 (11.0)

32

31

40

36

31

38

Education (%)
Low
Moderate

34

33

33

34

39

32

High

34

36

27

30

30

30

Body mass index (kg/m2)

26.2 (4.8)

25.9 (4.6)

24.9 (4.5)

29.7 (6.1)

31.1 (6.3)

28.4 (5.4)

Systolic blood pressure (mmHg)

140 (23)

131 (19)

131 (19)

148 (24)

145 (23)

138 (23)

Serum cholesterol (mmol/l)

6.0 (1.3)

5.5 (1.2)

5.6 (1.2)

6.0 (1.3)

5.7 (1.1)

6.0 (1.3)

Total physical activity (%)

a

Low

15

13

17

27

29

28

Moderate

82

83

80

71

70

70

High

3

4

3

2

1

2

those, who had smoked regularly but had stopped smoking at least six month before the survey
b
those who currently smoke or those who had stopped smoking less than six months before the survey
c
mean and standard deviation
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and ex-smoking in men without T2D was 40% and 26%,
respectively. Among women with T2D 13% were current
and 11% ex-smokers. The corresponding prevalence of
smoking and ex-smoking in women without T2D was
17% and 10%, respectively. People with T2D seemed to
have a higher prevalence of overweight and obesity,
lower levels of physical activity, higher serum cholesterol
and systolic blood pressure level than people without
diabetes at baseline or during follow-up. This pattern
was observed in both men and women.

smoking status. The CHD mortality risk for smoking men
with T2D was higher (HR 6.15; 95% CI 4.22-8.96) than in
non-smoking diabetic men (HR 2.62; 95% CI 1.60-4.29).
Similar results were found in women revealing corresponding HR for CHD mortality of 6.92 (95% CI
2.79-17.19) for smoking, T2D women and 4.06 (95%
CI 2.83-5.82) for non-smoking T2D women, respectively.
T2D patients that had stopped smoking also had a higher
risk of CHD mortality compared with non-smoking, diabetic men and women when adjusted for age, study area
and study year, education, systolic blood pressure, physical
activity, serum cholesterol and BMI (men: HR 4.30; 95% CI
3.04-6.08), women: HR 5.00; 95% CI 2.15-11.64). The HRs
of CHD mortality in smoke-free T2D patients was statistically significantly higher compared with non-smoking
people without T2D (men: HR 2.62; 95% CI 1.60-4.29;
women: HR 4.06; 95% CI 2.83-5.82).

T2D, smoking and all-cause mortality

The HRs for all-cause mortality were higher for T2D patients compared with men and women without T2D.
T2D patients who were smoking had higher all-cause
mortality in both men (HR 3.76; 95% CI 2.95-4.78) and
women (HR 4.51; 95% CI 2.91-7.00) than non-smoking
diabetic men (HR 2.03; 95% CI 1.51-2.74) and women
(HR 2.11; 95% CI 1.71-2.59) (Table 2). T2D patients that
had stopped smoking also had increased all-cause mortality compared with non-smoking, diabetic men and
women when adjusted for age, study area and study year,
education, systolic blood pressure, physical activity,
serum cholesterol and BMI (men: HR 2.56; 95% CI 2.043.22), women: HR 2.61; 95% CI 1.57-4.31).

T2D, smoking and CHD incidence

Smoking T2D patients had an increase in CHD incidence
compared with non-smoking people with and without
T2D (Table 4). The risk increase in smoking diabetic men
was 3.27-fold (95% CI 2.45-2.40) and 4.55-fold in women
(95% CI 2.48-8.33) when controlled for age, education,
systolic blood pressure, physical activity, serum cholesterol
and BMI. Even though the risk of CHD incidence in T2D
patients who had stopped smoking was statistically significantly higher than in their non-smoking non-diabetic

T2D, smoking and CHD mortality

Table 3 shows the hazard ratios for CHD mortality among
men and women with and without diabetes according to

Table 2 Hazard Ratio (HR) of all-cause mortality among men and women with and without diabetes at baseline according to
smoking status
Model Ab

Model Bc
a

Mortality rate

HR

95% CI

HR

95% CI

Non-diabetic, non-smokers

0.88

1

Refd

1

Ref

Non-diabetic, ex-smokers

1.52

1.46

1.29-1.66

1.38

1.21-1.57

Non-diabetic, smokers

1.93

2.98

2.65-3.35

2.63

2.33-2.97

Diabetic, non-smokers

2.63

2.22

1.66-2.95

2.03

1.51-2.74

Diabetic, ex-smokers

3.30

2.94

2.35-3.67

2.56

2.04-3.22

Diabetic, smokers

3.97

4.35

3.44-5.51

3.76

2.95-4.78

Non-diabetic, non-smokers

0.92

1

Ref

1

Ref

Non-diabetic, ex-smokers

0.44

1.27

1.02-1.59

1.30

1.04-1.63

0.85

2.41

2.06-2.81

2.37

2.02-2.78

Diabetic, non-smokers

2.43

2.40

1.96-2.94

2.11

1.71-2.59

Diabetic, ex-smokers

1.75

3.25

1.98-5.36

2.61

1.57-4.31

Diabetic, smokers

1.71

4.96

3.21-7.67

4.51

2.91-7.00

Men

Women

Non-diabetic, smokers

a

number of events per 100 person-years
b
adjusted for age, study area and study year
c
adjusted for age, study area, study year, education, systolic blood pressure, physical activity, serum cholesterol and BMI
d
reference group
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Table 3 Hazard Ratio (HR) of coronary heart disease (CHD) mortality among men and women with and without diabetes at baseline
according to smoking status
Model Ab

Model Bc

Mortality ratea

HR

95% CI

HR

95% CI

0.29

1

Refd

1

Ref

Men
Non-diabetic, non-smokers
Non-diabetic, ex-smokers

0.56

1.71

1.36-2.16

1.59

1.25-2.02

Non-diabetic, smokers

0.65

3.29

2.64-4.10

3.11

2.48-3.92

Diabetic, non-smokers

1.06

2.86

1.77-4.61

2.62

1.60-4.29

Diabetic, ex-smokers

1.63

5.28

3.77-7.40

4.30

3.04-6.08

Diabetic, smokers

1.73

6.98

4.85-10.03

6.15

4.22-8.96

Women
Non-diabetic, non-smokers

0.25

1

Ref

1

Ref

Non-diabetic, ex-smokers

0.08

1.33

0.74-2.37

1.40

0.78-2.51

Non-diabetic, smokers

0.20

3.43

2.40-4.89

3.84

2.65-5.55

Diabetic, non-smokers

0.96

4.81

3.37-6.85

4.06

2.83-5.82

Diabetic, ex-smokers

0.75

7.73

3.37-17.73

5.00

2.15-11.64

Diabetic, smokers

0.57

8.79

3.56-21.67

6.92

2.79-17.19

a

number of events per 100 person-years
adjusted for age, study area and study year
adjusted for age, study area, study year, education, systolic blood pressure, physical activity, serum cholesterol and BMI
d
reference group
b
c

Table 4 Hazard Ratio (HR) of coronary heart disease incidence among men and women with and without diabetes at baseline
according to smoking status
Model Ab

Model Bc
a

Incidence rate

HR

95% CI

HR

95% CI

Non-diabetic, non-smokers

0.69

1

Refd

1

Ref

Non-diabetic, ex-smokers

1.10

1.25

1.08-1.44

1.15

0.99-1.32

Non-diabetic, smokers

1.21

2.04

1.79-2.33

1.95

1.70-2.23

Diabetic, non-smokers

1.85

1.70

1.19-2.44

1.56

1.08-2.24

Men

Diabetic, ex-smokers

2.98

3.66

2.87-4.68

3.00

2.33-3.85

Diabetic, smokers

2.69

3.51

2.64-4.67

3.27

2.45-4.36

0.50

1

Ref

1

Ref

Women
Non-diabetic, non-smokers

a

Non-diabetic, ex-smokers

0.19

1.21

0.88-1.66

1.27

0.92-1.74

Non-diabetic, smokers

0.39

2.13

1.70-2.67

2.32

1.84-2.92

Diabetic, non-smokers

1.52

2.94

2.30-3.77

2.60

2.02-3.35

Diabetic, ex-smokers

0.99

3.59

1.91-6.76

2.80

1.48-5.30

Diabetic, smokers

1.24

5.37

3.02-9.58

4.55

2.48-8.33

number of events per 100 person-years
b
adjusted for age, study area and study year
c
adjusted for age, study area, study year, education, systolic blood pressure, physical activity, serum cholesterol and BMI
d
reference group
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counterparts, the CHD incidence was lower than in smoking T2D patients (HR in men 3.00; HR in women 2.80).

Discussion
This study showed that smoking men and women with
T2D had a higher risk of CHD incidence, and CHD and
all-cause mortality compared with non-smoking people
free of diabetes. Stopping smoking reduced the risk of allcause mortality in both men and women with T2D.
Whereas T2D patients who were not smoking or who had
stopped smoking had an increased risk of CHD incidence
and mortality, that increase seemed to be lower than the
one observed in their smoking diabetic counterparts.
As smoking may influence various mechanisms proposed
to increase the risk of CHD (e.g. vascular endothelial injury,
increased oxidative stress, thromboembolism), it is possible
that the effect of smoking on CHD and MI might be more
dramatically increased in diabetic patients, by a combination of short-term effects (coronary artery spasm, arrhythmias) and long-term effects (metabolic and thrombotic
disorders) on the cardiovascular system [23, 24]. In T2D
patients, smoking is an independent risk factor for CHD,
stroke and peripheral vascular disease [8, 25–27]. It accentuates the dyslipidemia of T2D that is associated with
increased hepatic lipase activity that may produce atherogenic, small, dense LDL particles [28].
In agreement with our study, the Nurses’ Health Study
showed that the age-adjusted incidence rate of total CHD
was much higher among diabetic women than among
non-diabetic women of similar smoking status. However,
they observed a considerably higher hazard ratio for CHD
among diabetic women than for non-diabetic women of
similar smoking status compared with our study [8] presenting a multivariate adjusted HR 7.7 for CHD in women
with T2D smoking more than 15 cigarettes/day compared
with non-diabetic, nonsmoking women [8]. Furthermore,
current smokers seem to be at higher risk than exsmokers in regard all-cause and CHD mortality. These
findings are in agreement with previous studies showing
that previous smokers might still suffer from the adverse
effects related to smoking even though the risk started to
decrease [8–10].
Most studies have compared mortality rates according
to smoking status among patients with T2D rather than
comparing mortality rates with the general population
[7, 9–11]. A cohort study involving 13 087 female and
male patients with T2D from the Swedish National Diabetes Register revealed statistically significant hazard ratios for smoking and first-incident fatal/nonfatal MI and
total mortality of 1.7 and 1.8, respectively [7]. The
Nurses’ Health Study reported that cigarette smoking
was associated in a dose–response manner with an increased mortality among women with type 2 diabetes [9]
and the United Kingdom prospective diabetes study
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found that hazard ratio for smokers in regard CHD of
1.41 (1.06 to 1.88) among a 7.9 year follow-up of 3055
T2D patients (10). Finally, a three year follow-up of 390
elderly T2D patients (mean age 73 years) showed an increased the risk of mortality 2.58 (95% CI 1.30–5.11)
among the smoking T2D patients compared with the
non-smoking ones [11].
Interestingly, some cohort studies did not find that
smoking increased the risk of CHD or all-cause mortality among T2D patients [12–17]. The Aerobics Center
Longitudinal Study included 2316 men with T2D which
were followed-up for almost 16 years [12] and the Rochester Epidemiology Project comprised 337 T2D patients
of Olmsted County, Minnesota [17]. Even though both
studies reported increased risks for current and exsmoking in regard CVD or all-cause mortality, this risk
increase did not reach statistical significance. Another
prospective population-based study of 400 patients with
T2D in Skara, Sweden revealed a 1.66-fold risk increase
for all-cause mortality among smokers compared with
non-smokers with a 95% CI of 0.99-2.76 [14]. Probably,
the latter two studies may have a low power to detect
risk increases due to a small sample size [14, 17]. Furthermore, both the ZODIAC-10 study and the Milan
Study on Atherosclerosis and Diabetes were lacking adequate adjustments of their results [15, 16, 18].
A recent meta-analysis of observational prospective studies assessing the excess risk of mortality and CVD events
associated with smoking among patients with diabetes revealed a relative risk comparing smokers with nonsmokers
of 1.48 for total mortality 1.54 for CHD [18]. Furthermore,
that excess risk was observed among former and current
smokers with a greater risk in current smokers.
The life-extending effect of successful smoking cessation
ultimately concerns every smoking patient in medical
practice and physicians should have an ethical obligation
to educate their patients about smoking and should not
hesitate to routinely advise to quit [29, 30]. In Finland, unfortunately, smoking is not discussed during most routine
health care consultations with smokers if they do not
present any “smoking-related” disease [31]. Physicians
should ask their patients whether they smoke, how much
they smoke, and whether they are willing to quit. As a
subsequent step one should explain to every smoking patient why and to what extent smoking cessation would,
for medical reasons, favorably change their future health.
This short talk hardly takes more than two minutes [29].
It has been shown that if the patient presents CHD, approximately eight out of ten Finnish primary care physicians give smoking cessation advice to that specific
population group [31]. However, smoking counseling
should be given long before the patients have CHD and
especially if they have T2D as pointed out in the current
clinical guidelines for diabetes care [32].
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Naturally, our study had some limitations. The baseline assessment of our cohort is limited to the examination on a single day when participants entered the
study, as typical for large cohort studies. It cannot account for changes in lifestyle or risk factors of CHD disease leading to a shift of participants between categories
during the study period. Furthermore, we cannot completely exclude the effects of confounding due to some
unmeasured dietary and other lifestyle factors that may
influence CHD or all-cause mortality. In addition, assessing smoking habits by questionnaire may lack some of
accuracy as we did not have information regarding packyears or intensity of smoking. However, self-reported
smoking habits are commonly used in epidemiological
studies and seem to be rather accurate when compared
with biochemical markers of tobacco use.

Conclusions
It is important to address tobacco consumption in T2D
patients in primary health-care in order to reduce their
risk of CHD and all-cause mortality. Smoking cessation
programs should be offered to each T2D patient and
former smoking T2D patients should be encouraged to
remain smoke-free. As smoking and ex-smoking T2D
patients have a higher risk of CHD incidence and mortality, their health status with regard to CHD should be
carefully checked during their annual follow-up control
visits with health care personnel.
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